Michael Reff, RPh, MBA, Founder and Executive Director of the National Community Oncology Dispensing Association (NCODA), explains the need for practices and pharmacists to learn about rare cancers so they are better prepared to provide quality patient care. Watch as he discusses the importance of Quality Initiatives for patients with myeloproliferative neoplasms (MPNs).
Watch Neal Dave, PharmD, Pharmacy Area Manager, Texas Oncology, explain the importance of using a Quality Initiative to monitor for clinical characteristics such as hematocrit and white blood cell counts that may indicate advancing disease in patients with PV.
Watch Julianne Orr Darling, PharmD, BCOP, an Oncology and Clinical Pharmacist at Indiana University Health, discuss the importance of taking a proactive approach to risk stratification when managing patients with MF. Review risk stratification criteria and how pharmacists can create a list of patients for a potential Quality Initiative. Watch this video and download a brochure about MF risk below as a PDF.

A Rationale for Quality Initiatives for Patients With MPNs
This presentation focuses on how multidisciplinary teams can champion Quality Initiatives in patients with myeloproliferative neoplasms. You can learn about trends, better understand the clinical rationale for different types of Quality Initiatives, read about real world examples of MPN Quality Initiatives, and get tips for implementing Quality Initiatives in your practice.
View Slide Deck
Polycythemia Vera (PV) Brochure
Use this brochure when implementing a Quality Initiative to help clinicians proactively identify the subset of patients with clinical characteristics of advanced PV who would benefit from better management. Learn more about the risk of thrombotic events, mortality rate, elevated blood counts, and symptom burden in advanced PV. And see how using EHR systems can help with identification of these patients.
Download PDF
Quality Initiative Implementation
Get an overview of why Quality Initiatives (QIs) for patients with myeloproliferative neoplasms (MPNs) are important, the steps in the process, and the types of MPN QIs to consider.
Download PDF
Cerner EMR Guide for Advanced Polycythemia Vera (PV) Patient Pursuit List
If you have a Cerner EMR, this guide can help you when implementing a PV Quality Initiative. It is designed to provide step-by-step instructions to create a patient list identifying patients who may have clinical characteristics of advanced PV, and discusses quality outcomes goals, as well as NCCN and professional organization guidelines.
Download PDF
Symptom Burden Quality Initiative Brochure
Learn about proactively identifying patients with myeloproliferative neoplasms (MPNs) who have burdensome symptoms and how better management of these symptoms can impact a patient’s quality of life.
Download PDF
Epic EMR Guide for Advanced Polycythemia Vera (PV) Patient Pursuit List
If you have an Epic EMR, this guide can help you when implementing a PV Quality Initiative. It is designed to provide step-by-step instructions to create a patient list identifying patients who may have clinical characteristics of advanced PV, and discusses quality outcomes goals, as well as NCCN and professional organization guidelines.
Download PDF
Identifying Risk and Setting Up Quality Initiatives for Patients With Myelofibrosis (MF)
Get information that may help you identify and evaluate risk profiles among your patients with MF. You will also find risk stratification guidelines and insights into strategies for assessing and monitoring risk.
Download PDF
Onco EMR Guide for Advanced Polycythemia Vera (PV) Patient Pursuit List
If you have an Onco EMR, this guide can help you when implementing a PV Quality Initiative. It is designed to provide step-by-step instructions to create a patient list identifying patients who may have clinical characteristics of advanced PV, and discusses quality outcomes goals, as well as NCCN and professional organization guidelines.
Download PDF